Pfizer announced that a Phase 3 randomized withdrawal design study for Lyrica in patients with inadequately treated painful diabetic peripheral neuropathy did not meet its primary efficacy endpoint. READ MORE
Source: Marketwatch
May
01
- What is PN
- Living Well with PN
- Research
- Make a Difference
- What is PN
- Living Well with PN
- Research
- Make a Difference
News
Recent Posts
- FPN Welcomes New Board Member in February
- What is Metabolic Syndrome, What does it have to do with Neuropathy, and What can we do about it?
- Key Data from FPN Patient Registry Highlighted in Top Medical Journal
- Mike’s Story: How I Keep My Exercise Goals
- Gene Therapy Blocks Peripheral Nerve Damage in Mice
Categories
Archives
- February 2019
- January 2019
- December 2018
- October 2018
- September 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- March 2015
- February 2015
- October 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- June 2011
- May 2011
- April 2011
- November 2010
- April 2010
- January 2010
- January 2009
- January 2008
© Copyright 2016 The Foundation for Peripheral Neuropathy.
Comments are closed.